4128.TWO Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (7 Mai 2024 @ 07:30):

Stats
Tagesvolumen	1.09M
Durchschnittsvolumen	1.61M
Marktkapitalisierung	23.16B
EPS	TWD-0.890 ( 2023-09-30 )
Nächstes Ertragsdatum	( TWD0 ) 2024-05-30
Last Dividend	TWD0 ( N/A )
Next Dividend	TWD0 ( N/A )
P/E	-19.60
ATR14	TWD0.0300 (0.07%)

Volumen Korrelation

Lang: -0.04 (neutral)

Kurz: -0.66 (moderate negative)

Signal:(45.126) Neutral

Microbio Co., Ltd. Korrelation

10 Am meisten positiv korreliert

10 Am meisten negativ korreliert

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Microbio Co., Ltd. Korrelation - Währung/Rohstoff

0.43
( neutral )

0.47
( neutral )

0.00
( neutral )

0.08
( neutral )

0.04
( neutral )

-0.58
( weak negative )

Microbio Co., Ltd. Finanzdaten

Annual	2023
Umsatz:	TWD1.59B
Bruttogewinn:	TWD380.42M (23.90 %)
EPS:	TWD-2.11

FY	2023
Umsatz:	TWD1.59B
Bruttogewinn:	TWD380.42M (23.90 %)
EPS:	TWD-2.11

FY	2022
Umsatz:	TWD1.72B
Bruttogewinn:	TWD691.30M (40.15 %)
EPS:	TWD0.270

FY	2021
Umsatz:	TWD1.78B
Bruttogewinn:	TWD739.37M (41.49 %)
EPS:	TWD0.104

Financial Reports:

No articles found.

Microbio Co., Ltd.

Microbio Co., Ltd. researches, develops, manufactures, and trades in biotech drugs and dietary supplements in Taiwan. The company provides MS-20 for ameliorating fatigue and appetite loss associated with cancer chemotherapy; and Herbiron, which reveals symptoms of iron deficiency anemia and menstrual discomfort. Its pre-clinical stage products include SNA-03 and SNA-07 for cancer immune therapy; SNP-630 to treat non-alcoholic steatohepatitis; FB918 for the treatment of non-allergic eosinophilic asthma; and SNS812 for Cov-flu. The company's Phase I clinical trial products consist of OB-318, an anti-cancer drug; MB-110 for the treatment of hepatitis C; SNP-810, an acetaminophen; FB317 to treat moderate-to-severe allergic asthma and chronic idiopathic urticaria; and FB704A for the treatment of rheumatoid arthritis, cancer, cytokine storms, etc. It also offers FB825, which is in Phase II clinical trial for the treatment of atopic dermatitis, allergic asthma, hyper IgE syndrome, and food allergy. In addition, the company's Phase III clinical trial products comprise ON101 to treat diabetic foot ulcer; and MB-6 that acts as an adjuvant for metastatic colorectal cancer. Further, its discovery stage pipeline includes FB121 for AIDS; SNA01 to treat PD-1 related cancer; SNA02 for cancer immune therapy; and SNS01 for recurrent metastatic non-small cell lung cancer. Additionally, the company develops SNP-830 and SNP-840, a hepatotoxicity-free analgesic. It is also involved in the trading of organic foods; sale of beverages; provision of technology development, transfer, and consultation services; and publishing of magazine, as well as offers business consulting services. Microbio Co., Ltd. was founded in 2000 and is based in Taipei, Taiwan.